ATE442379T1 - Bildgebende agentien auf basis bizyklischer peptide - Google Patents

Bildgebende agentien auf basis bizyklischer peptide

Info

Publication number
ATE442379T1
ATE442379T1 AT04743485T AT04743485T ATE442379T1 AT E442379 T1 ATE442379 T1 AT E442379T1 AT 04743485 T AT04743485 T AT 04743485T AT 04743485 T AT04743485 T AT 04743485T AT E442379 T1 ATE442379 T1 AT E442379T1
Authority
AT
Austria
Prior art keywords
bizyclic
peptides
imaging agents
agents based
compounds
Prior art date
Application number
AT04743485T
Other languages
English (en)
Inventor
Alan Cuthbertson
Magne Solbakken
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE442379T1 publication Critical patent/ATE442379T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Light Receiving Elements (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04743485T 2003-07-30 2004-07-21 Bildgebende agentien auf basis bizyklischer peptide ATE442379T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317815.9A GB0317815D0 (en) 2003-07-30 2003-07-30 Imaging agents
PCT/GB2004/003150 WO2005012335A1 (en) 2003-07-30 2004-07-21 Imaging agents

Publications (1)

Publication Number Publication Date
ATE442379T1 true ATE442379T1 (de) 2009-09-15

Family

ID=27799463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743485T ATE442379T1 (de) 2003-07-30 2004-07-21 Bildgebende agentien auf basis bizyklischer peptide

Country Status (24)

Country Link
US (2) US7410943B2 (de)
EP (1) EP1648925B1 (de)
JP (1) JP4625002B2 (de)
KR (1) KR101153529B1 (de)
CN (1) CN1829735B (de)
AT (1) ATE442379T1 (de)
BR (1) BRPI0412986A (de)
CA (1) CA2533321C (de)
CY (1) CY1109522T1 (de)
DE (1) DE602004023092D1 (de)
DK (1) DK1648925T3 (de)
ES (1) ES2332722T3 (de)
GB (1) GB0317815D0 (de)
HK (1) HK1097278A1 (de)
HU (1) HUP0600230A3 (de)
IL (1) IL173029A0 (de)
MX (1) MXPA06001090A (de)
NO (1) NO20060825L (de)
NZ (1) NZ544583A (de)
PL (2) PL210122B1 (de)
PT (1) PT1648925E (de)
RU (2) RU2355702C2 (de)
SI (1) SI1648925T1 (de)
WO (1) WO2005012335A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CA2568601A1 (en) * 2004-06-16 2005-12-29 Ge Healthcare As Peptide-based compounds
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
AU2005307195A1 (en) 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
EP1940841B9 (de) 2005-10-07 2017-04-19 Guerbet Verbindungen mit einem eine biologische zielstruktur erkennenden teil, das mit einem zum komplexieren von gallium fähigen signalteil gekoppelt ist
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8148575B2 (en) 2006-04-20 2012-04-03 Hammersmith Imanet Limited Radiofluorinated compounds and their preparation
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2118123B1 (de) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilisierte p53-peptide und deren verwendungen
EP3301108A1 (de) 2007-02-23 2018-04-04 Aileron Therapeutics, Inc. Makrocyclische systeme von triazol
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
GB0722650D0 (en) 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
US8877970B2 (en) * 2008-01-09 2014-11-04 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
JP5399422B2 (ja) * 2008-02-28 2014-01-29 ジーイー・ヘルスケア・リミテッド 市販の安価な化学薬品からのpeg−6成分の合成
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
EP2480565A4 (de) 2009-09-22 2014-01-01 Aileron Therapeutics Inc Peptidomimetische makrozyklen
US20120229804A1 (en) 2009-12-21 2012-09-13 Medi-Physics, Inc. Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f- ion
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
PL2621496T5 (pl) 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201511036D0 (en) 2015-06-23 2015-08-05 Guy S And St Thomas Hospital Nhs Foundation Trust Imaging method
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230525T2 (de) 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
DE60111733T2 (de) 2000-04-12 2006-05-18 Amersham Health As Integrinbindende peptidderivate
AU2001288847A1 (en) * 2000-09-07 2002-03-22 Biosyntema Inc. Conformationally constrained labeled peptides for imaging and therapy
IL141276A0 (en) * 2001-02-05 2002-03-10 Peptor Ltd Backbone cyclized radiolabelled somatostatin analogs
HU230901B1 (hu) 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113000001A (zh) * 2021-03-22 2021-06-22 洛阳海惠新材料股份有限公司 一种用于制备pbat的增粘连体反应器
CN113750923A (zh) * 2021-08-30 2021-12-07 桐昆集团浙江恒腾差别化纤维有限公司 一种酯化反应回收系统

Also Published As

Publication number Publication date
US20060193773A1 (en) 2006-08-31
DK1648925T3 (da) 2010-01-04
HUP0600230A3 (en) 2009-09-28
RU2006102324A (ru) 2007-09-20
HUP0600230A2 (en) 2007-01-29
KR101153529B1 (ko) 2012-06-11
PL210122B1 (pl) 2011-12-30
NO20060825L (no) 2006-03-29
JP2007523880A (ja) 2007-08-23
WO2005012335A1 (en) 2005-02-10
US20080267881A1 (en) 2008-10-30
JP4625002B2 (ja) 2011-02-02
IL173029A0 (en) 2006-06-11
EP1648925B1 (de) 2009-09-09
NZ544583A (en) 2009-12-24
CA2533321C (en) 2012-09-18
CN1829735B (zh) 2010-05-26
GB0317815D0 (en) 2003-09-03
EP1648925A1 (de) 2006-04-26
US7811551B2 (en) 2010-10-12
PL1648925T3 (pl) 2010-02-26
HK1097278A1 (en) 2007-06-22
SI1648925T1 (sl) 2010-01-29
MXPA06001090A (es) 2006-04-24
CA2533321A1 (en) 2005-02-10
PT1648925E (pt) 2009-12-10
RU2009105640A (ru) 2010-08-27
PL379705A1 (pl) 2006-11-13
BRPI0412986A (pt) 2006-10-03
CN1829735A (zh) 2006-09-06
DE602004023092D1 (de) 2009-10-22
RU2355702C2 (ru) 2009-05-20
ES2332722T3 (es) 2010-02-11
CY1109522T1 (el) 2014-08-13
KR20060090795A (ko) 2006-08-16
US7410943B2 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
ATE442379T1 (de) Bildgebende agentien auf basis bizyklischer peptide
ATE519776T1 (de) Peptidische verbindungen
MXPA04000173A (es) Compuestos basados en peptidos.
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
NZ521735A (en) Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
BRPI0411617A (pt) derivados de pirimidina como ligantes de receptores de canabinóides
BRPI0409634A (pt) ligantes de receptores de canabinóides e utilização destes
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
BRPI0410289A (pt) ligantes do receptor de canabinóides e suas utilizações
DE60217854D1 (de) Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung
ATE500271T1 (de) Fluoresceinmarkierte peptide
ATE425770T1 (de) Kontrastmittel
ATE480552T1 (de) Stq-peptide
MX2009006028A (es) Compuestos basados en peptido radiomarcado y usos de los mismos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648925

Country of ref document: EP